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Abstract
Background: Small interfering RNAs (siRNAs) are double-stranded RNAs that effectively inhibit expression of its
complimentary target mRNA. Standard siRNAs contain two nucleotide overhangs on their 3’ end. While these
overhangs are usually comprised of deoxythymidines (dT), it has been shown that any nucleotide can be used on
the 3’ end without affecting RNAi silencing.
Results: It was recently shown that extension of the 3’ end to five or eight dT molecules allows siRNAs to be
effectively complexed with linear polyethylenimine (PEI), leading to enhanced cellular uptake and intracellular
release. Here, we provide further evidence that only extended or ‘sticky’ siRNAs complexed with PEI result in
significant target knockdown. However, when investigating the potential effects of these extended siRNAs on
growth of human colon cancer RKO cells, we observed a dose-dependent reversal of cytotoxicity of a thymidylate
synthase-targeted siRNA. In contrast, siRNAs with uridine overhangs maintained their growth inhibitory effects. We
further demonstrated that dT-containing siRNAs prevented the cytotoxic effects of thymidylate synthase (TS)
inhibitor compounds, such as ZD1694 and 5’-fluoro-deoxyuridine, while having no deleterious effect on cisplatin
toxicity. We show that this rescue effect results from the rapid degradation of the siRNA.
Conclusions: Given that TS is an important enzyme for cell growth and proliferation and that its expression is
controlled by multiple pathways, the rescue of its growth inhibitory effects may have unintended consequences.
As siRNAs are being developed as therapeutic molecules, it will be important to avoid such off-target effects due
to dT release. Hence, siRNAs should contain only uridine residues in their 3’-end overhangs.
Background
Thymidylate synthase (TS) is a folate-dependent enzyme
that catalyzes the reductive methylation of deoxyuridine
monophosphate (dUMP) to deoxythymidine monopho-
sphate (dTMP) [1]. Once synthesized, dTMP is subse-
quently metabolized intracellularly to deoxythymidine
triphosphate (dTTP), a key nucleotide for DNA replica-
tion and repair. Although dTMP can be formed via the
salvage pathway, a reaction catalyzed by thymidine
kinase, the TS-catalyzed reaction provides the only
intracellular de novo source of dTMP. As such, inhibi-
tion of this enzymatic step results in suppression of
cellular growth and proliferation. Given the central role
that TS plays in cellular proliferation, TS has been an
important target for cancer chemotherapy for over
40 years [2,3].
Previous studies from our lab identified a small inter-
fering RNA (siRNA) directed against the 3’-untranslated
region (UTR) of human TS mRNA that was able to
potently and specifically inhibit TS expression [4]. This
siRNA exhibited a high level of specificity for TS mRNA
as we were unable to identify off-target effects. In addi-
tion, this molecule effectively prevented the induction of
TS protein following exposure to TS inhibitor com-
pounds, such as the fluoropyrimidine 5-fluorodeoxyuri-
dine and various antifolate analogs. Furthermore,
treatment with this siRNA restored chemosensitivity to
resistant human colon cancer RKO-HTStet cells that
overexpressed TS by 15-fold. This work provided new
insights towards the development of siRNAs as potential
novel therapeutic molecules.
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siRNA therapeutics are their specificity and efficiency of
delivery into target cells. Significant efforts have been
placed, therefore, on developing nanoparticle technolo-
gies to facilitate siRNA cellular uptake. A wide range of
molecules have been developed as delivery systems, and
they include cationic lipids, carbon nanotubes, poly(lac-
tic-coglycolic) acid (PLGA), polyethylenimine (PEI), pep-
tides, dendrimers, and silicon and gold microparticles
[5-11]. PEI has been used as an effective DNA plasmid
delivery vehicle but has limited capacity for siRNA deliv-
ery [5,12]. Recently, Bolcato-Bellemin and colleagues
extended the 3’ end of the siRNA creating longer com-
plimentary overhangs of five or eight nucleotides,
thereby allowing PEI to effectively deliver these siRNA
molecules into cells [13]. They hypothesized that the
‘sticky’ siRNAs or sticky end siRNAs (ssiRNAs) form
gene-like concatemers with greater electrostatic interac-
tion with PEI, thereby resulting in less cell surface poly-
anion exchange, enhanced cellular uptake, and
eventually greater intracellular release of siRNA. Herein,
we provide further evidence for the ability of PEI to effi-
ciently deliver extended siRNAs, but not standard siR-
NAs, into human colon cancer RKO cells. As we further
investigated the effects of the 3’ overhangs on cell
growth, we observed that the extended TS-targeted
ssiRNA displayed a reduced level of cytotoxicity. Our
findings show that as the siRNA is degraded, the deox-
ythymidine (dT) nucleotides on the 3’ end are released,
which then rescues cells from the cytotoxic effects of
the TS-targeted siRNA. Additionally, we demonstrate
that this release of dTMP from siRNA degradation is
able to rescue cells from the cytotoxic effects of TS inhi-
bitor compounds. The potential implication of these
findings on the therapeutic efficacy of TS-associated
cancer chemotherapy is discussed.
Results
The use of siRNAs to target and suppress specific
genes has been a significant advance in studies of gene
expression and function. However, the potential role of
siRNAs as therapeutic molecules has been limited, in
large part due to issues relating to stability, cellular
uptake, and specificity of delivery into target tissues.
Significant efforts have focused on developing delivery
systems that encapsulate the siRNA in nanoparticles
and then target the nanoparticle with small peptides,
molecules, and/or antibodiesa g a i n s tt i s s u e - s p e c i f i c
and/or tumor-specific receptors. Commercially avail-
able cationic lipids have been available for many years
and represent ideal tools for cell culture delivery of
nucleic acids. As seen in Figure 1, Lipofectamine 2000
(LF2000) was able to deliver the TS6 TS-targeted
siRNA into human RKO colon cancer cells resulting in
> 95% knockdown of the target protein (Figure 1, lane
2). While LF2000 has been widely used for in vitro tis-
sue culture experiments, these lipid carriers have not
been used for in vivo studies as they are associated with
alteration of gene expression profiles, increased host
toxicities, and activation of host immune response
[14-17]. A different cationic molecule, PEI, has been
used for in vitro and in vivo delivery of both DNA
plasmids and siRNA [8,12]. However, we were unable to
knockdown TS expression with linear PEI in combina-
tion with TS6 siRNA (Figure 1, lane 4). Bolcato-
Bellemin et al. recently showed that PEI can deliver
siRNA when the siRNA 3’-end overhangs, normally two
deoxythymidine nucleotidesi nl e n g t h ,a r ee x t e n d e dt o
either five or eight nucleotides [13]. The overhangs on
either end of the siRNA are made complimentary to
allow for the formation of long gene-like concatemers
that allow them to be effectively complexed by PEI and
then released once inside the cell. This extended siRNA
is termed ‘sticky’ siRNA or ssiRNA. When the TS6
siRNA was modified with 5 dT on the sense strand and
5 deoxyadenosine (dA) on the antisense strand to form
TS6 ssiRNA, PEI was able to efficiently deliver and
release TS6 ssiRNA into human colon cancer RKO
cells, resulting in enhanced knockdown of TS protein
levels (Figure 1, lane 5). As an important control, the
modified mismatch control ssiRNA complexed with PEI
had absolutely no effect on expression of TS protein
(Figure 1, lane 6).
To determine the effect of these extensions at the
3’-end of the siRNA on the ability of the siRNA to inhi-
bit cell growth, we performed a series of cell prolifera-
tion experiments. At a concentration of 10 nM, TS6
ssiRNA suppressed cell growth by 50% (Figure 2a).
However, at higher ssiRNA concentrations, the growth
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Figure 1 Comparison of Lipofectamine 2000 (LF2000) and
polyethylenimine (PEI) for siRNA transfection. RKO cells were
transfected with TS6 siRNAs (100 nM) complexed either LF2000
(lanes 1-3) or linear jetPEI (lanes 4-6). After 48 h, cells were
harvested and processed for western blot analysis as described in
the Methods section. Lane 1 contains cell lysates from LF2000-
treated cells; lane 2, TS6 siRNA; lane 3, TS6 mismatch siRNA; lane 4,
TS6 siRNA; lane 5, TS6 sticky end siRNA (ssiRNA); lane 6, TS6
mismatch ssiRNA.
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concentration of ssiRNA tested (300 nM), cell growth
was minimally suppressed compared with untreated cells.
We then synthesized an ssiRNA containing deoxyuridine
(dU) instead of dT overhangs on the sense strand for
comparison with the dT/dA ssiRNA (the antisense strand
still contained 5 dA overhangs). As seen in Figure 2a,
treatment with the dU-containing ssiRNA yielded a simi-
lar level of suppression of cell growth at 10 nM as the
dT-ssiRNA. However, at higher concentrations, the
growth inhibitory effects were not reversed as observed
with treatment with the dT-ssiRNA. One possible expla-
nation is that the dT-containing sense strand, upon
release from the RISC, was being degraded intracellularly,
resulting in the release of dTMP. This nucleotide is even-
tually metabolized within the cell to the dTTP tripho-
sphate metabolite, which is an essential precursor for
DNA biosynthesis and DNA repair. Once formed, dTTP
would be able to rescue against the cytotoxic effects of
the TS6 siRNA. We next determined whether this effect
Figure 2 Effect of ssiRNA/siRNA transfection on RKO cell growth. (a) RKO cells were transfected with TS6 ssiRNA containing dTx5 (black
bars) or dUx5 overhangs (gray bars) at the indicated concentrations. (b) RKO cells were transfected with TS6 siRNA containing dTdT (black bars)
or dUdU overhangs (gray bars) at the indicated concentrations. After 96 h, a WST-1 cell proliferation assay was performed. Mock-transfected cells
(LF2000 alone) were normalized to 100%. Values represent the mean ± standard error of the mean (SEM) from at least four separate experiments
performed in duplicate. *P values < 0.01 versus dT-containing ssiRNAs or siRNAs at the same concentration.
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dard dTdT overhangs. As seen in Figure 2b, TS6 siRNA
has significantly less inhibitory effect on growth of RKO
cells at all concentrations when compared to the siRNA
with dU overhangs. Of note, addition of 10 μMt h y m i -
dine to the cell culture medium completely reversed the
growth inhibitory effects after 10 nM ssiRNA/siRNA
transfection (96% ± 5 vs LF2000-treated cells). This pro-
tective effect has been previously reported by us and
others using the same siRNA sequence [4,18].
To confirm that TS protein and TS mRNA levels were
decreased after siRNA transfection, western blot and
quantitative (q)PCR analyses were performed. As shown
in Figure 3a, transfection of 10 nM of either TS6
ssiRNA resulted in > 90% decrease in TS protein. Upon
300 nM transfection, TS protein was undetectable. Simi-
lar observations were seen after standard TS6 siRNAs
resulting in > 84% knockdown of TS protein after
10 nM transfection. Analysis of the relative levels of TS
mRNA after transfection with the various siRNAs
Figure 3 Effect of ssiRNA/siRNA transfection on TS protein and mRNA expression.R K Oc e l l sw e r et r a n s f e c t e dw i t hT S 6s i R N A su s i n g
LF2000. After 48 h, cells were harvested for western blot (a) or qPCR analysis (b) as described in the Methods section. (a) Representative
western blot from three similar experiments. The percentage TS protein knockdown was quantified after scanning and analysis by ImageJ
software. (b) Relative mRNA levels after siRNA transfection. Values represent the mean ± standard deviation (SD) from three individual
experiments analyzed in triplicate. TS/18S values were normalized to the value of cells treated with LF2000 alone, which was set to 100.
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blot analysis (Figure 3b).
To support the hypothesis that dTMP release was
potentially rescuing the cytotoxicity caused by siRNA-
mediated TS inhibition, we performed a series of growth
experiments combining dT-ssiRNA with the TS inhibitor
ZD1694 (also known as TDX). This antifolate compound
is a specific inhibitor of TS, and its inhibitory effects on
cell growth are completely reversed with the addition of
exogenous thymidine in the cell culture medium [19,20].
Exposure of RKO cells to 3 nM ZD1694 resulted in 85%
growth suppression (Figure 4a). When the sense strand
alone (containing 5xdT 3’-end overhang) was transfected
simultaneously with 3 nM ZD1694, a dose-dependent
rescue from the ZD1694 cytotoxic effects was observed.
RNA concentrations as low as 30 nM demonstrated sig-
nificant enhancement of cell growth. At the highest con-
centration used in this experiment (300 nM), the growth
inhibitory effects of ZD1694 were completely reversed.
As an important control, 300 nM of the sense strand
Figure 4 Effect of RNA/ssiRNA/siRNA transfection on ZD1694 toxicity. RKO cells were exposed to 3 nM ZD1694 (TDX) with or without (a)
RNA, (b) ssiRNA, or (c) siRNA transfection. After 96 h, cell growth was determined by the WST-1 assay. Untreated cells (LF2000 alone) were
normalized to 100%. Values represent the mean ± standard error of the mean (SEM) from at least four separate experiments performed in
duplicate. *P values < 0.05 versus ZD1694 treatment alone.
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inhibitory effects of ZD1694. Similarly, no rescue effect
was observed when RKO cells were treated with the anti-
sense strand containing the 5xdA overhang.
While a single-stranded RNA is most likely degraded
rapidly to individual nucleotides, it was not clear as to
whether the double-stranded ssiRNA, once transfected
and incorporated into the RNA-induced silencing com-
plex (RISC), would degrade rapidly enough to release
sufficiently high levels of dTMP. To determine the effect
of transfection of the double-stranded ssiRNA on
ZD1694 cytotoxicity, the TS6 mismatch ssiRNA was
transfected into RKO cells. Since TS6 ssiRNA has effects
on cell growth, we chose the mismatch ssiRNA as it had
absolutely no effects on growth of RKO cells on its own.
As observed with the single-stranded dT-containing
RNA, the TS6 mismatch ssiRNA was also able to
reverse the inhibitory effects of ZD1694. In contrast, a
TS6 mismatch ssiRNA with 5xdU overhangs was unable
to reverse ZD1694 cytotoxicity (Figure 4b).
To determine if standard siRNAs would have the same
impact on the growth inhibitory effects of ZD1694 as
extended ssiRNAs, a series of experiments were con-
ducted with the mismatch siRNA. As seen in Figure 4c,
siRNAs with dTdT overhangs were able to reverse
ZD1694 toxicity in a dose-dependent fashion. These
results were not significantly different from those utiliz-
ing ssiRNA (Figure 4b). Since siRNAs contain four dT
molecules per siRNA and the ssiRNA contain five dT
molecules per ssiRNA, it is not surprising that their abil-
ity to rescue from ZD1694 toxicity is virtually identical.
Two additional dTdT-containing siRNAs targeting other
mRNAs (firefly luciferase and human epidermal growth
factor receptor 2 (HER2)) were also able to reverse
ZD1694 toxicity (data not shown). However, the TS
mismatch siRNA containing dUdU overhangs was
unable to reverse drug toxicity. In addition to ZD1694,
the cytotoxicity of 5’-fluoro-2’-deoxyuridine was
reversed by transfection of the dTdT-containing mis-
match but the toxicity of a non-TS-directed inhibitor
compound such as cisplatin was not reversed by the
mismatch siRNA (data not shown).
To determine whether degradation of the ssiRNA was
rapid enough to release dTMP for ZD1694 rescue, we
performed a series of pulse-chase experiments. RKO
cells were transfected with 10 nM TS6-dTx5 ssiRNA.
After 6 h, the culture medium was replaced and cellular
RNA was extracted after various times followed by
northern blot analysis. As seen in Figure 5a, control
RNAs (sense and ssiRNA) were readily detected by the
antisense probe whereas the antisense RNA was not
seen. ssiRNA isolated from transfected RKO cells was
also observed at all time points. No smaller RNA degra-
dation products were observed, which may suggest that
once the RNA is targeted for degradation, it is rapidly
degraded. However, the absence of smaller-sized RNAs
may be due to limitations of the siRNA northern blot
analysis, as the 25-nucleotide antisense probe may not
bind with sufficiently high affinity to smaller sense
RNAs. The estimated half-life of the TS6-dTx5 siRNA
in RKO cells was 13.2 ± 1.6 h (n = 3). To determine
whether this is sufficient time to permit rescue of TS
inhibition, cell growth studies were performed with
ZD1694 and thymidine. The cytotoxicity of ZD1694 can
be completely reversed by thymidine addition 8 h after
ZD1694 (Figure 5b). In contrast, the addition of thymi-
dine 24 h after ZD1694 treatment results in only partial
rescue. Taken together, these findings suggest that the
dT-containing ssiRNA was being rapidly degraded
resulting in the intracellular release of dTMP, which can
then rescue cells from TS inhibition caused by either
siRNA or small molecule inhibitors.
Discussion
In this study, we investigated the use of ‘sticky’ siRNAs as
potential therapeutic molecules for targeting TS. Previous
work by Bolcato-Bellemin et al. demonstrated that stan-
dard siRNAs are not tightly bound to the cationic deliv-
ery molecule PEI and are exchanged for cell surface
polyanionic syndecans resulting in their release prior to
cellular uptake [13]. They discovered that extension of
the 3’ end of the sense strand by either five or eight deox-
ythymidine molecules (with complimentary deoxyadeno-
sine molecules on the antisense strand) allowed these
Figure 5 siRNA northern blot analysis. (a) TS6-dTx5 ssiRNA was
transfected into RKO cells. After 6 h, the cell culture medium was
replaced. RNA was extracted using Trizol immediately and after an
additional 24 and 48 h followed by northern blot analysis as
described in the Methods section. (b) Thymidine rescue of ZD1694
toxicity. RKO cells were incubated with 3 nM ZD1694 in the
presence or absence of 10 uM thymidine. Thymidine (10 μM) was
also added 8 and 24 h after ZD1694 addition. After an additional
72 h, cell proliferation was quantified by the WST-1 assay. Cell
growth values represent the mean ± standard deviation (SD) from
three experiments performed in duplicate.
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and ultimately released after cellular uptake. Our studies
provide further evidence that this modification results in
effective delivery of TS6 ssiRNA with linear PEI.
As with any modification to a potential ‘drug’ mole-
cule, we wanted to ensure that the 3’ extensions did not
affect the ability of the siRNA to inhibit cell growth. Sur-
prisingly, higher concentrations of TS6 ssiRNA with dT
overhangs displayed significantly less inhibitory effect on
RKO cell growth. However, transfection of a TS-targeted
ssiRNA with dU overhangs maintained the inhibitory
effects on cell growth over the concentration range
tested. This observation was also true for standard siR-
NAs with two dTdT nucleotide overhangs. Thus, our
findings suggest that as the siRNA is degraded into its
nucleotide components, free dTMP is released into cells
and eventually metabolized to the dTTP metabolite,
which is then able to prevent the cytotoxic effects of the
TS-targeted siRNA. This observation provides a reason-
able explanation for our earlier work, which showed that
cell growth was inhibited by at most 30% using siRNAs
containing dTdT overhangs despite a > 95% reduction in
TS protein expression [4]. The difference in cell growth
observed here compared to this previous work (50% ver-
sus 30% growth suppression) may also be attributed to
the use of OPTI-MEM medium (Invitrogen). This
enhanced culture medium, which is commonly used for
in vitro transfections, contains 3 μM thymidine, and this
level of thymidine may have contributed, in part, to the
reduced growth effect of TS6 siRNA.
Given the possibility of cell growth rescue, we deter-
mined whether such dTMP release from the degraded
siRNA could reverse the cytotoxicity of TS inhibitor
compounds. Both siRNAs and ssiRNAs containing dT
overhangs reversed ZD1694 toxicity in a dose-dependent
fashion. However, the respective siRNA and ssiRNA
molecules with dU overhangs were unable to rescue
cells providing supportive evidence that the reversal of
cell growth inhibition is, in fact, due to dTMP release.
We further showed that the ssiRNA is degraded intra-
cellularly with an approximate half-life of 13 h. Exogen-
ous addition of thymidine 8 to 24 h after ZD1694
treatment was able to reverse cytotoxicity, suggesting
that the degradation of ssiRNAs provides for sufficiently
high levels of free dTMP for drug rescue.
This observation has clear therapeutic relevance as
siRNA high-throughput screens are being used to iden-
tify possible candidate genes for therapeutic interven-
tion. A screen containing dTdT-siRNAs targeting
thousands of genes and utilizing cell proliferation or cell
migration as a selection predictor may only identify
genes with little to no effect on the TS pathway and/or
TS-associated pathways as the dTdTs would reverse
growth effects from TS-influenced genes. The use of
such screens may therefore result in misinterpretation
of the observed findings. Furthermore, this observation
has clinical importance as siRNAs are presently being
actively developed in clinical trials. A recent clinical
study utilized dT-containing siRNAs to prevent lung
infection of the respiratory syncytial virus [21]. Given
the essential role of TS in cell growth and differentia-
tion, the efficient rescue of its growth effects by dT-
siRNAs may have unintendedc o n s e q u e n c e so ns i R N A
therapeutics. Presently, the general consensus is that
nearly every gene may be ‘targetable’ with siRNAs. How-
ever, many of these potential therapeutic targets may
have either direct or indirect effects on TS expression.
For example, inhibition of both epidermal growth factor
receptor (EGFR) and HER2 with the small molecule
inhibitor lapatanib has been shown to downregulate TS
protein expression which, in turn, can then sensitize
cells to fluorouracil (5-FU) and the oral fluoropyrimi-
dine capecitabine [22]. There are other potential protein
targets that may influence and/or regulate TS expres-
sion, and they include calcium-sensing receptor (CaSR),
E2F1, C-MYC, late SV40 factor (LSF), astrocyte elevated
gene 1 (AEG-1), cyclin-dependent kinase 4 (CDK4), and
histone deacetylases (HDAC) [22-29]. With respect to
HDACs, clinical trials are ongoing to take advantage of
the inhibitory effect of HDAC inhibitors on TS expres-
sion by combining them with fluoropyrimidines in var-
ious clinical regimens [30]. If a HDAC-specific siRNA
was used in place of the small molecule HDAC inhibi-
tor, it is conceivable that the dTdT overhangs would
rescue from TS inhibition, resulting in a reduced thera-
peutic efficacy.
It is certain that as the critical issues of stability and
tissue delivery are resolved, siRNAs will move from
being a genetic research tool to therapeutic drug mole-
cules. Significant attention has focused on the potential
off-target effects of siRNAs. These effects include pas-
senger strand targeting and miRNA-like effects [31]. To
our knowledge, this is the first report of off-target
effects resulting directly from siRNA degradation. As
new nucleotide modifications are incorporated into the
siRNA backbone, careful attention must be given as to
the potential consequences these degraded modified
nucleotides might have on cellular metabolism, signal-
ing, and growth. Based on our findings, siRNAs should
be designed so that they incorporate only uridine resi-
dues in the 3’-overhang position, especially when the
target gene may, in some manner, be related to the TS-
signaling pathway.
Methods
siRNAs
siRNA and ssiRNA duplexes were obtained from Dhar-
macon Research (Lafayette, CO, USA). The synthesis of
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(sequences listed in Table 1). The luciferase GL2 siRNA
(#D-001100; 5’-CGUACGCGGAAUACUUCGA-’3) and
a HER2-targeting siRNA (5’-UCUUAGACGAAG-
CAUACGU-’3) containing standard dTdT 3’-end over-
hangs were also obtained from Dharmacon.
Cell culture
The human colon cancer RKO cell line, originally
obtained from the American Type Culture Collection
(ATCC), has been previously well characterized and was
maintained in our laboratory at 37°C in 75 cm
2 tissue
culture flasks (BD Bioscience, San Jose, CA, USA) in
RPMI-1640 growth medium containing 10% dialyzed
fetal bovine serum [4]. RKO cells are routinely authenti-
cated by morphology and growth curve analysis. Cells
were tested periodically for Mycoplasma by the MycoA-
lert Mycoplasma detection assay (Cambrex Bio Science,
Rockland, ME, USA).
siRNA transfection
Cells were plated in six-well plates at a density of 1 ×
10
5 cells per well. The following day, siRNA duplexes
were complexed with LF2000 (Invitrogen, Carlsbad, CA,
USA) in serum-free RPMI-1640 medium or linear jetPEI
(Polyplus Transfection Inc., New York, NY, USA) in
4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid
(HEPES)-buffered saline as described by the manufac-
turer’s protocol and added to the plated cells. After
48 h, the wells were rinsed with phosphate-buffered sal-
ine (PBS), and cells were scraped in cell lysis buffer
(10 mM Tris pH 7.4, 150 mM NaCl, 1 mM ethylenedia-
minetetra-acetic acid (EDTA), 1%
octylphenoxypolyethoxyethanol (IGEPAL), 0.5% deoxy-
cholic acid, and 0.1% SDS) containing freshly added Pro-
tease Inhibitor Cocktail (Sigma, St Louis, MO, USA) and
1 mM phenylmethanesulfonylfluoride (PMSF). Lysates
were sonicated three times at 3 s each and centrifuged
at 10,000 g for 10 min at 4°C. Cell lysates were stored at
-80°C for future use. For mRNA analysis, cells were
rinsed with PBS, and incubated with Trizol (Invitrogen).
Total RNA was stored at -80°C for future use.
Western immunoblot analysis
Protein concentrations of cell lysates were determined
using the DC Protein Assay (Bio-Rad, Hercules, CA,
USA). Equivalent amounts of protein (50 μg) from each
cell lysate were resolved on SDS-PAGE using the
method of Laemmli [32]. Gels were electroblotted onto
nitrocellulose membranes (0.45 μm; Bio-Rad), and mem-
branes were then incubated in blocking solution
(1XPBS, 0.1% Tween-20, 5% non-fat dry milk powder)
for 1 h at room temperature. Membranes were incu-
bated at 4°C overnight with primary antibodies at the
following dilutions: anti-TS monoclonal antibody,
1:5,000 (Zymed Laboratories, San Francisco, CA, USA);
anti-a-tubulin monoclonal antibody 1:5,000 (EMD Bios-
ciences, Gibbstown, NJ, USA). After multiple 1XPBS,
0.1% Tween-20 (PBST) washes, membranes were incu-
bated with a dilution of 1:10,000 of horseradish peroxi-
dase-conjugated secondary antibody (goat anti-mouse
IgG; Bio-Rad) for 1 h at room temperature. After addi-
tional PBST washes, membranes were processed by the
enhanced chemiluminescence method (SuperSignal
West Pico substrate; Pierce, Rockford, IL, USA), and
protein bands were visualized by autoradiography.
Quantitation of signal intensities was performed by den-
sitometry on a Hewlett Packard ScanJet 5370C (Hewlett
Packard, Palo Alto, CA, USA) using NIH ImageJ soft-
ware (http://rsbweb.nih.gov/ij/).
Cell growth assays
RKO cells were plated in 96-well plates at a density of
800 cells/well. The following day, cells were transfected
with siRNA/LF2000 complexes and allowed to incubate
for 96 h. Cell proliferation and viability was quantified
by the WST-1 assay (Roche Applied Science, Indianapo-
lis, IN, USA). For ZD1694 rescue experiments, a con-
centration of 3 nM ZD1694 was added simultaneously
with the siRNA complexes.
Real-time quantitative reverse transcriptase (qRT)-PCR
analysis
The first-strand cDNA was synthesized using 0.5 μg total
RNA and the Quantitect Reverse Transcription Kit
(Qiagen Inc., Valencia, CA, USA). The real-time PCR was
performed in triplicates using the Taqman Gene
Table 1 Small interfering RNA (siRNA) sequences
siRNA Sequence
TS6-dTdT 5’- GGAUAUUGUCAGUCUUUAGG-dTdT-’3
3’-dTdT- CCUAUAACAGUCAGAAAUCC-’5
TS6-dUdU 5’- GGAUAUUGUCAGUCUUUAGG-dUdU-’3
3’-dUdU- CCUAUAACAGUCAGAAAUCC-’5
TS6-dTx5 5’- GGAUAUUGUCAGUCUUUAGG-
dTdTdTdTdT-’3
3’-dAdAdAdAdA- CCUAUAACAGUCAGAAAUCC-’5
TS6-dUx5 5’- GGAUAUUGUCAGUCUUUAGG-
dUdUdUdUdU-’3
3’-dAdAdAdAdA- CCUAUAACAGUCAGAAAUCC-’5
Mismatch-
dTx5
5’- GGAUACUGCCAAUCUCUAGG-
dTdTdTdTdT-’3
3’-dAdAdAdAdA- CCUAUGACGGUUAGAGAUCC-’5
These siRNAs target nucleotides 1106-1123 of human thymidylate synthase
(TS) mRNA. The top strand is the sense (passenger) strand with the bottom
strand being the antisense (guide) strand of the siRNA. Mismatches are shown
in bold type.
dA = deoxyadenosine; dT = deoxythymidine; dU = deoxyuridine.
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CA, USA) in a final reaction volume of 20 μl with gene-
specific primer/probe sets, and a standard thermal cycling
procedure (40 cycles) on a Mastercycler EP realplex
instrument (Eppendorf, Hamburg, Germany). The mRNA
level of TS and 18s RNA was assessed using the TaqMan
Gene Expression real-time PCR assays (Applied Biosys-
tems, assay IDs: Hs00426586_m1 and Hs03928990_g1,
respectively). The results were expressed as the threshold
cycle (CT). The relative quantification of the target tran-
scripts was determined by the comparative Ct method
(ΔΔCt) according to the manufacturer’sp r o t o c o l( U s e r
Bulletin No. 2, Applied Biosystems). The 2
-ΔΔCt method
was used to analyze the relative changes in gene expres-
sion between LF2000-treated cells and siRNA/LF2000-
treated cells. Control experiments without reverse tran-
scription were performed to confirm that the total RNA
contained no genomic DNA contamination.
siRNA northern blot analysis
RKO cells were transfected with 10 nM TS6-dTx5
ssiRNA complexed with LF2000. After 6 h, the transfec-
tion medium was removed and total RNA was extracted
from cells using Trizol. For 24 and 48 h time points,
fresh growth medium was added back to the wells, and
cells were harvested for total RNA at time. Total RNA
(2-5 μg) was loaded onto a native 20% acrylamide gel
and electrophoresed for 90 min at 450 V. Single-
stranded and double-stranded RNAs were included in
each gel as negative and positive controls. To account
for RNA dilution due to cell growth, total RNA isolated
from the same number of cells was used for each time
point. The RNAs were transferred onto BrightStar-Plus
positively charged nylon membrane (Ambion, Austin,
TX, USA) using the GENIE blotter (Idea Scientific, Min-
neapolis, MN, USA) in 1XTris/borate/EDTA (TBE). The
antisense strand of TS6 ssiRNA was 5’-end labeled using
T4 kinase (Promega, Madison, WI, USA) and [P
32]-ATP.
After prehybridizing the membrane, the antisense probe
was added to Northern Max Hybridization Buffer
(Ambion) and incubated with the membrane at 37°C
overnight. The membrane was washed with 2X saline-
sodium citrate (SSC)/0.1% SDS and 0.2X SSC/0.1% SDS
buffer before being exposed to film. Quantitation of sig-
nal intensities was performed by densitometry on a
Hewlett Packard ScanJet 5370C using NIH ImageJ
software.
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